Asset profile
Mezigdomide
Small molecule
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-01-10.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mezigdomide: this drug | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Pomalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Cereblon (CRBN) | ||
| Thalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Iberdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| ICP-490 | Phase 1/2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| TQB3820 | Phase 1 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (7)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (2)
July 2027 (2)
December 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
2029 (2)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
2035 (1)
December 2035 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.